 "Dr Reddy's launches anti-SRE drug in US")
The launch follows US Food and Drug Administration's (USFDA) approval of its abbreviated new drug application for the drug.
A bio-equivalent generic version of Zometa (zoledronic acid), which is sold under the Reclast and Zometa brand names in the US, the drug is indicated for the prevention of skeletal-related events (SREs) in multiple types of advanced cancer involving the bone.
The zoledronic acid injection 4 mg/5 ml is available in a single-use vial of concentrate, Dr Reddy's said in a press release on Tuesday.
Dr Reddy's scrip is currently trading at Rs 1,782.90 on the BSE, up 1.06%, over the previous close of Rs 1,764.15 a share.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%